What is the clinical evidence from this study?

Study design: Cohort. Population: Cardio-kidney metabolic (CKM) diseases (n=16415). Intervention: History of cancer vs. No history of cancer. Primary outcome: CKM stage progression (HR 0.63, 95% CI 0.47-0.83, p=<0.01).

What question did this study set out to answer?

To explore the prevalence and progression of cardio-kidney metabolic diseases among Hispanic cancer survivors.

April 5, 2026

Abstract 2339: Cardio-kidney metabolic health among adult cancer survivors in the Hispanic Community Health Study/Study of Latinos.

Q: What are the key findings of this study?

Hispanic adult cancer survivors were less likely to experience CKM stage progression than those without a cancer history after accounting for competing mortality (HR 0.63; 95% CI 0.47-0.83; P<0.01).

Q: What question did this study set out to answer?

To explore the prevalence and progression of cardio-kidney metabolic diseases among Hispanic cancer survivors.

Key Result

Hispanic adult cancer survivors were less likely to experience CKM stage progression than those without a cancer history after accounting for competing mortality (HR 0.63; 95% CI 0.47-0.83; P<0.01).

Key Points

To explore the prevalence and progression of cardio-kidney metabolic diseases among Hispanic cancer survivors.
Utilized data from the Hispanic Community Health Study with 16,415 participants.
Stratified participants by cancer history and assessed changes in CKM stages over six years.
Employed multivariable logistic and Fine-Gray competing risk models to analyze associations.
Cancer survivors had a higher prevalence of advanced CKM stages at both visits (24.2% vs 10.0% at Visit 1).
Higher mortality rates observed in cancer survivors (12.2% vs 4.8%) during follow-up.
After adjusting for demographics, cancer history was not a significant predictor of CKM worsening.

Study Design

Type

Cohort (n=16,415)

Structured PICO

Does a history of cancer predict cardio-kidney metabolic (CKM) disease progression in Hispanic/Latino adults?

Population

16,415 Hispanic/Latino adults from the community-based Hispanic Community Health Study/Study of Latinos (HCHS/SOL), including participants with a history of cancer (n=644) and without a history of cancer (n=15,771).

Intervention

History of cancer

Comparator

No history of cancer

Outcome

Cardio-kidney metabolic (CKM) stage progression over an average of six yearscomposite

While Hispanic cancer survivors have a higher baseline prevalence of advanced CKM stages and higher mortality, a history of cancer itself does not independently predict further CKM stage progression after accounting for competing mortality.

Main Result

Effect estimate: HR 0.63 (95% CI 0.47-0.83)

p-value: p=<0.01

Abstract

Abstract Background: Compared to the general population, cancer survivors are at higher risk for cardiovascular, kidney, and metabolic (CKM) diseases. However, the prevalence and progression of CKM diseases among Hispanic/Latino adults with a history of cancer remain underexplored. Using data from the community-based Hispanic Community Health Study/Study of Latinos (HCHS/SOL), we examined the changes in CKM diseases and predictors of CKM disease progression over an average of six years, stratified by baseline cancer history. Methods: We included 16, 415 participants from the HCHS/SOL with a history of cancer (n=644) and without a history of cancer (n=15, 771) at Visit 1 in 2008-2011. CKM stage at Visit 1 and Visit 2 in 2014-2017 was defined according to the 2023 American Heart Association (AHA) ’s CKM stage framework. The 2023 AHA advisory defines five CKM stages (0-4), progressing from no CKM risk factor (stage 0) to excess or dysfunctional adiposity (stage 1), metabolic syndrome or chronic kidney disease (stage 2), subclinical cardiovascular disease or risk equivalent (stage 3), and established cardiovascular disease (stage 4). Descriptive statistics were used to assess the prevalence and transition of CKM stage between visits. Survey-weighted multivariable logistic models and Fine-Gray competing risk models were used to evaluate the associations (odds ratios, ORs, and 95% confidence intervals, CIs) between cancer history and sociodemographic factors and CKM stage progression. Results: Compared to those without a history of cancer, those with a history of cancer were older (mean age±standard error = 55. 8±1. 0 versus 47. 4±0. 2 years), more likely to be female (65. 4% versus 52. 7%), retired (29. 0% versus 10. 6%), have an annual household income 20, 000 (54. 9% versus 47. 5%), and be physically inactive (45. 0% versus 36. 4%). Cancer survivors had a higher prevalence of advanced CKM stages (≥ stage 3) at both Visit 1 (24. 2% versus 10. 0%) and Visit 2 (35. 3% versus 16. 9%). While the proportions of CKM worsening were similar between groups, cancer survivors had a significantly higher mortality rate (12. 2% vs 4. 8%) during follow-up. Cancer history itself was not a predictor of CKM worsening after adjusting for sociodemographic factors (OR = 1. 03; 95% CI = 0. 75-1. 43). After accounting for competing mortality, cancer survivors were 37% less likely to experience CKM stage progression than those without a cancer history (HR = 0. 63; 95%CI = 0. 47-0. 83; P0. 01). Conclusion: CKM diseases are prevalent among Hispanic adults, with cancer survivors experiencing more advanced CKM stages and higher mortality rates over time than those without a history of cancer. Citation Format: Myunhee Lee, Matthew Allison, Linda C. Gallo, Carlos Rosas, Daniela Sotres-Alvarez, Frank J. Penedo, Martha Daviglus, James Lash, Humberto Parada. Cardio-kidney metabolic health among adult cancer survivors in the Hispanic Community Health Study/Study of Latinos abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (7 Suppl): Abstract nr 2339.

Bookmark